Collplant Biotechnologies Company Leadership
| CLGN Stock | USD 3.30 0.04 1.23% |
Collplant Biotechnologies employs about 75 people. The company is managed by 8 executives with a total tenure of roughly 25 years, averaging almost 3.0 years of service per executive, having 9.38 employees per reported executive. Analysis of Collplant Biotechnologies' management performance can provide insight into the firm performance.
| Yehiel Tal CEO CEO Director |
| Ilana Belzer President Vice President - Operations |
Collplant |
Collplant Biotechnologies' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Collplant Biotechnologies' future performance. Based on our forecasts, it is anticipated that Collplant will maintain a workforce of about 80 employees by March 2025.Collplant Biotechnologies Management Team Effectiveness
The company has return on total asset (ROA) of (0.3822) % which means that it has lost $0.3822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7065) %, meaning that it created substantial loss on money invested by shareholders. Collplant Biotechnologies' management efficiency ratios could be used to measure how well Collplant Biotechnologies manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of February 2025, Return On Tangible Assets is likely to drop to -0.2. In addition to that, Return On Capital Employed is likely to drop to -0.23. At this time, Collplant Biotechnologies' Total Assets are very stable compared to the past year. As of the 25th of February 2025, Other Current Assets is likely to grow to about 283.1 K, while Non Current Assets Total are likely to drop about 3.8 M.As of the 25th of February 2025, Common Stock Shares Outstanding is likely to grow to about 13.8 M, while Net Loss is likely to drop (20.4 M).
Collplant Biotechnologies Workforce Comparison
Collplant Biotechnologies is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,639. Collplant Biotechnologies holds roughly 75.0 in number of employees claiming about 2.84% of equities under Health Care industry.
Collplant Biotechnologies Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Collplant Biotechnologies Price Series Summation is a cross summation of Collplant Biotechnologies price series and its benchmark/peer.
Collplant Biotechnologies Notable Stakeholders
A Collplant Biotechnologies stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Collplant Biotechnologies often face trade-offs trying to please all of them. Collplant Biotechnologies' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Collplant Biotechnologies' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Yehiel Tal | CEO Director | Profile | |
| Ilana Belzer | Vice President - Operations | Profile | |
| Oren Fahimipoor | Vice Operations | Profile | |
| Michal Roytman | VP Marketing | Profile | |
| Pr Shoseyov | Founder Scientist | Profile | |
| Eran CPA | Deputy CFO | Profile | |
| Elana Gazal | Vice Development | Profile | |
| Hadas Horowitz | Vice Resources | Profile |
About Collplant Biotechnologies Management Performance
The success or failure of an entity such as Collplant Biotechnologies often depends on how effective the management is. Collplant Biotechnologies management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Collplant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Collplant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.20) | |
| Return On Capital Employed | (0.22) | (0.23) | |
| Return On Assets | (0.21) | (0.19) | |
| Return On Equity | (0.22) | (0.23) |
Collplant Biotechnologies Workforce Analysis
Traditionally, organizations such as Collplant Biotechnologies use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Collplant Biotechnologies within its industry.Collplant Biotechnologies Manpower Efficiency
Return on Collplant Biotechnologies Manpower
| Revenue Per Employee | 146.1K | |
| Revenue Per Executive | 1.4M | |
| Net Loss Per Employee | 93.6K | |
| Net Loss Per Executive | 877.4K | |
| Working Capital Per Employee | 330.3K | |
| Working Capital Per Executive | 3.1M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collplant Biotechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share | Quarterly Revenue Growth (0.91) | Return On Assets | Return On Equity |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.